Drugs & Therapy Perspectives

, Volume 17, Issue 9, pp 1–6 | Cite as

Linzolid: first of a new drug class for Gram-positive infections

New drugs and disease management

Keywords

Adis International Limited Linezolid Soft Tissue Infection Neisseria Gonorrhoeae Chlamydial Infection 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Diekema D, Jones R. Oxazolidinones: a review. Drugs 2000; 59(1): 7–16PubMedCrossRefGoogle Scholar
  2. 2.
    Clemett D, Markham A. Linezolid. Drugs 2000; 59(4): 815–27PubMedCrossRefGoogle Scholar
  3. 3.
    Perry CM, Jarvis B. Linezolid: a review of its use in the management of serious Gram-positive infections. Drugs 2001; (61) 4: 525–551CrossRefGoogle Scholar
  4. 4.
    Pharmacia and Upjohn Company. Kalamazoo, USA. Linezolid prescribing information. Available from: URL: http://www.zyvox.com/fullprescribe.htm [Accessed 2001 Apr 12]
  5. 5.
    Wise R. Linezolid: a viewpoint by Richard Wise. Drugs 2000; 59(4): 828CrossRefGoogle Scholar
  6. 6.
    Zurenko GE, Yagi BH, Schaadt RD, et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996; 40: 839–45PubMedGoogle Scholar
  7. 7.
    Schaadt RD, Batts DH, Daley-Yates PT, et al. Serum inhibitory titers and serum bactericidal titers for human subjects receiving multiple doses of the antibacterial oxazolidinones eperezolid and linezolid. Diagn Microbiol Infect Dis 1997; 28: 201–4PubMedCrossRefGoogle Scholar
  8. 8.
    Cammarata SK, Hafkin B, Demke DM, et al. Efficacy of linezolid in skin and soft tissue infections [abstract]. Clin Microbiol Infect 1999; 5 Suppl. 3: 133Google Scholar
  9. 9.
    Cammarata SK, Hafkin B, Todd WM, et al. Efficacy of linezolid in community-acquired S. pneumoniae pneumonia [abstract]. Am J Respir Crit Care Med 1999; 159 Suppl. Pt 2 (3): A844Google Scholar
  10. 10.
    Anon. First resistance to linezolid reported. Scrip Mag 1999 Oct 6; 2478: 23Google Scholar
  11. 11.
    Lobeck F, Anderson DC, Bruss JB, et al. Linezolid for the treatment of pneumonia in hospitalized children: an open-label, single-arm, multicenter study [abstract]. 9th International Congress on Infectious Diseases; Apr 10–13: Buenos Aires, 117Google Scholar
  12. 12.
    Birmingham MC, Zimmer GS, Hafkin B, et al. Outcomes with linezolid from an ongoing compassionate use (CU) trial of patients (pts) with significant, resistant Gram-positive infections [abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Nov 18–24; Buffalo, NY: 724Google Scholar
  13. 13.
    Birmingham MC, Zimmer GS, Flavin SM, et al. Results of treating bacteraemic patients with linezolid in a compassionate use trial for resistant, gram-positive infections [abstract]. Proceedings of the 37th Annual Meeting of the Infectious Diseases Society of America; 1999 Nov 18–21; Philadelphia, PA: 129Google Scholar
  14. 14.
    Duvall SE, Sseas C, Bruss JB, et al. Comparison of oral linezolid to oral Clarithromycin in the treatment of uncomplicated skin infections: results from a multinational phase III trial [abstract]. 9th International Congress on Infectious Diseases; 2000 Apr 10–13: Buenos Aires, 181Google Scholar
  15. 15.
    Cammarata SK, Schueman LK, Timm JA, et al. Oral linezolid in the treatment of community-acquired pneumonia: a phase III trial [poster no. E-73]. American Thoracic Society; 2000 May 5: TorontoGoogle Scholar
  16. 16.
    Stevens DL, Smith LG, Bruss JB, et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000; 44(12): 3408–13PubMedCrossRefGoogle Scholar
  17. 17.
    Cammarata SK, San Pedro GS, Timm JA, et al. Comparison of linezolid versus ceftriaxone/cefpodoxime in the treatment of hospitalized patients with community-acquired pneumonia [poster no. 237]. American Thoracic Society 2000 May 5, TorontoGoogle Scholar
  18. 18.
    Cammarata SK, Hempsall KA, Timm JA, et al. Linezolid is superior to Cephalosporins in treatment of patients with bacteremic Streptococcus pneumoniae community-acquired pneumonia [abstract]. Am J Resp Crit Care Med 2000; 161 Pt 2 suppl. A654Google Scholar
  19. 19.
    Leach TS, Kaja RW, Eckert SM, et al. Linezolid versus vancomycin for the treatment of MRS A infections: results of a randomized phase III trial [abstract]. 9th International Congress on Infectious Diseases; 2000; Apr 10–13: Buenos Aires, 224Google Scholar
  20. 20.
    Rubinstein E, Cammarata SK, Oliphant TH, et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2000; 32: 402–12CrossRefGoogle Scholar
  21. 21.
    Hartman CS, Leach TS, Kaja RW, et al. Linezolid in the treatment of vancomycin-resistant enterococcus: a dose comparative, multicenter phase III trial [abstract]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20: Toronto, 488Google Scholar
  22. 22.
    Fines M, Leclercq R. Influence of mechanisms of resistance to antiobiotics that bind to the 50S ribosomal subunit on the activity of linezolid against gram-positive organisms. Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29; San Francisco, CA: C183Google Scholar
  23. 23.
    Zurenko GE, Todd WM, Hafkin B, et al. Development of linezolid-resistant Enterococcus faecium in two compassionate use program patients treated with Linezolid [abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 24–2; San Francisco, CA: 118Google Scholar
  24. 24.
    Wilks NE, McConnell-Martin MA, Oliphant TH. Safety and tolerance of linezolid in phase II trials [abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 24–27; San Francisco, CA: 40Google Scholar
  25. 25.
    Noskin GA. Linezolid: a viewpoint by Gary A. Noskin. Drugs 2000; 59(4): 828CrossRefGoogle Scholar
  26. 26.
    Rittenhouse BE, Li Z, Willke RJ, et al. Re-examining hospital length of stay (LOS) reduction potential in a randomized, multi-center clinical trial of methicillin-resistant Staphylococcal species (MRSS): linezolid vs. vancomycin [abstract]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20: Toronto, 510Google Scholar
  27. 27.
    Li ZJ, Willke RJ, Pinto LA, et al. Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy 2001; 21(3): 263–274PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2001

Personalised recommendations